Circulating CD137
4-1BB
CD137
HNSCC
anti-PD1
immunotherapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
12 Apr 2023
12 Apr 2023
Historique:
received:
02
03
2023
revised:
06
04
2023
accepted:
11
04
2023
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Pembrolizumab, an anti-PD-1 antibody, has been approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma ((R/M) HNSCC). However, only a minority of patients benefit from immunotherapy, which highlights the need to identify novel biomarkers to optimize treatment strategies. CD137
Identifiants
pubmed: 37108276
pii: ijms24087114
doi: 10.3390/ijms24087114
pmc: PMC10138766
pii:
doi:
Substances chimiques
pembrolizumab
DPT0O3T46P
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sapienza University of Rome
ID : RP122181610A7266
Organisme : Sapienza University of Rome
ID : RM12117A7B767D0D
Organisme : Sapienza University of Rome
ID : RM12117A85361029
Organisme : Sapienza University of Rome
ID : RM120172B803DB14
Organisme : Sapienza University of Rome
ID : RM1221816BCE0EA
Organisme : Italian Association for Cancer Research
ID : 17432
Références
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Head Neck. 2016 Dec;38(12):1855-1861
pubmed: 27405247
Cell Mol Immunol. 2011 Jul;8(4):281-4
pubmed: 21217771
Front Oncol. 2021 Nov 25;11:787864
pubmed: 34900743
N Engl J Med. 2008 Sep 11;359(11):1116-27
pubmed: 18784101
Cancer Discov. 2013 Jul;3(7):761-9
pubmed: 23619167
Cancer Treat Rev. 2020 Mar;84:101977
pubmed: 32018128
JAMA Oncol. 2019 Feb 1;5(2):195-203
pubmed: 30383184
Head Neck. 2019 Aug;41(8):2789-2800
pubmed: 30821023
PLoS One. 2020 Feb 24;15(2):e0229089
pubmed: 32092078
J Immunol. 1999 Nov 1;163(9):4833-41
pubmed: 10528184
Nat Commun. 2017 Sep 19;8(1):592
pubmed: 28928380
Cancer Sci. 2022 Apr;113(4):1475-1487
pubmed: 35100464
Blood. 2009 Oct 15;114(16):3431-8
pubmed: 19641184
Semin Cancer Biol. 2018 Oct;52(Pt 2):228-240
pubmed: 29355614
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
Lancet Oncol. 2017 Aug;18(8):1104-1115
pubmed: 28651929
Curr Oncol. 2022 Jun 08;29(6):4185-4198
pubmed: 35735443
Eur J Immunol. 1998 Mar;28(3):881-90
pubmed: 9541583
Front Med (Lausanne). 2021 Apr 27;8:640515
pubmed: 33987192
Int J Cancer. 2014 Dec 15;135(12):2857-67
pubmed: 24789574
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Ann Oncol. 2020 Jul;31(7):942-950
pubmed: 32294530
Clin Cancer Res. 2017 Apr 15;23(8):1929-1936
pubmed: 27756788
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Blood. 2010 Mar 11;115(10):1941-8
pubmed: 20068221
J Immunol. 2001 Aug 1;167(3):1313-24
pubmed: 11466348
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Cancer Immunol Res. 2018 Jun;6(6):711-722
pubmed: 29700053
Biomedicines. 2022 Oct 05;10(10):
pubmed: 36289746
Bioanalysis. 2011 Feb;3(4):383-9
pubmed: 21338257
Arch Oral Biol. 2020 Jun;114:104717
pubmed: 32344357
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
EBioMedicine. 2020 Dec;62:103098
pubmed: 33166793
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
J Immunother. 2019 Jul/Aug;42(6):215-220
pubmed: 31145232
J Cancer Res Ther. 2021 Jul;17(3):676-687
pubmed: 34269299
Am J Clin Pathol. 2001 Apr;115(4):543-9
pubmed: 11293902
Clin Cancer Res. 2014 Jan 1;20(1):44-55
pubmed: 24045181
Clin Cancer Res. 2022 Mar 01;28(5):1027-1037
pubmed: 34980602
Clin Cancer Res. 2017 Jun 1;23(11):2713-2722
pubmed: 28476872
Int J Mol Sci. 2022 Nov 21;23(22):
pubmed: 36430974
Clin Cancer Res. 2019 Jul 15;25(14):4211-4223
pubmed: 30814108
J Clin Oncol. 2017 May 10;35(14):1542-1549
pubmed: 28328302
Eur J Immunol. 2008 Apr;38(4):1024-32
pubmed: 18395851
Hepatology. 2020 Mar;71(3):955-971
pubmed: 31353502
Front Immunol. 2022 Sep 02;13:988416
pubmed: 36119046